1. Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?
- Author
-
Moccia, Alden A., Zucca, Emanuele, and Ghielmini, Michele
- Subjects
- *
B cell lymphoma , *RITUXIMAB , *THERAPEUTIC use of monoclonal antibodies , *LYMPHOMA treatment , *CANCER chemotherapy , *IMMUNOTHERAPY , *TUMOR treatment - Abstract
Rituximab (R) is an anti-CD20 monoclonal antibody which has become an essential component for the treatment of B-cell lymphomas. When associated to chemotherapy it improves the outcome of the patients with diffuse large B-cell lymphoma, follicular lymphoma, and other lymphoproliferative diseases in comparison to chemotherapy alone. For patients with newly diagnosed follicular lymphoma achieving at least a partial response to initial immuno-chemotherapy, maintenance R was associated with an improvement in progression-free survival and a meta-analysis of randomized maintenance trials suggests an overall survival advantage. The role of maintenance R in other indolent diseases is less well-defined. In this article, we summarize the data available for this strategy in less frequent subtypes of indolent B-cell lymphomas. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF